ACELYRIN Announces Additional Phase 2 Data And Phase 3 Program Design For Lonigutamab In Thyroid Eye Disease; Patients Demonstrate Potential For Efficacy In Line With Standard Of Care And A More Favorable Safety Profile
ACELYRIN Announces Additional Phase 2 Data And Phase 3 Program Design For Lonigutamab In Thyroid Eye Disease; Patients Demonstrate Potential For Efficacy In Line With Standard Of Care And A More Favorable Safety Profile
Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile
觀察到的甲狀腺眼病（TED）患者在皮下使用lonigutamab的全部數據顯示其在標準護理下具有潛在療效，並且安全性更爲理想。
Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025
進行了積極的第二階段FDA會議；第三階段計劃預計在2025年第一季度啓動。
Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027
第三階段的頂線數據預計在2026年下半年發佈；現金續航預計到2027年中期。
Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET
將於2025年1月6日（今天）東部時間下午4:30舉行電話會議，審查TED的未滿足需求、新的第二階段數據和第三階段項目設計。
LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease (TED). The Company will host a virtual investor event today, Monday, January 6, 2025 at 4:30 PM ET. To register, click here.
洛杉磯，2025年1月6日（全球新聞通訊） -- ACELYRIN, INC.（納斯達克：SLRN），一家關注加速轉化醫學在免疫學領域開發和交付的晚期臨牀生物製藥公司，今日宣佈了lonigutamab在甲狀腺眼病（TED）中的額外第二階段數據和第三階段項目設計。公司將在2025年1月6日（週一）東部時間下午4:30舉辦虛擬投資者活動。要註冊，請點擊這裏。
譯文內容由第三人軟體翻譯。
